Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 19

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Mantle cell lymphoma

Recruiting

A study to evaluate the effectiveness of pirtobrutinib in elderly and frail patients with mantle cell lymphoma who have not yet received treatment.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Fondazione Italiana Linfomi Ets

Acute myeloid leukaemia

Recruiting

Study of Revumenib, Cytarabine, and Fludarabine in Children with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Pediatric Research International GmbH

Acute myeloid leukaemia

Recruiting

Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

Neoplasm malignant

Recruiting

A study to evaluate the safety and effectiveness of H-CYS(SS)-GLU-VAL-SER-GLN-LEU-LEU-LYS-GLY-ASP-ALA-CYS(SS)-OH in patients with advanced solid tumors who have completed other treatments.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Apmonia Therapeutics

Plasma cell myeloma

Recruiting

A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Squamous cell carcinoma of lung+6

Recruiting

A study to evaluate the safety and effectiveness of BNT324 and BNT327 in patients with advanced lung cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE

Non-small cell lung cancer

Recruiting

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Gastric cancer+2

Recruiting

A study to evaluate the use of FAPI-46 (68Ga) imaging to detect peritoneal cancer spread in patients with colorectal, gastric, ovarian, or pancreatic cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
  • Sponsor:GE Healthcare Limited

Acute leukaemia

Recruiting

A study of Enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Sumitomo Pharma America Inc.

K-ras gene mutation+1

Recruiting

Evaluation of Safety, Pharmacokinetics, and Efficacy of RO7782493 and Panitumumab in Advanced Solid Tumors with KRAS G12D Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:Genentech Inc.

Squamous cell carcinoma of the hypopharynx+1

Recruiting

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Centre Leon Berard

Breast cancer metastatic

Recruiting

Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Stemline Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.